Huang et al., 2019 - Google Patents
LINGO-1 deficiency promotes nerve regeneration through reduction of cell apoptosis, inflammation, and glial scar after spinal cord injury in miceHuang et al., 2019
View HTML- Document ID
- 7569512858517503120
- Author
- Huang L
- Li G
- Ding Y
- Sun J
- Wu T
- Zhao W
- Zeng Y
- Publication year
- Publication venue
- Experimental Neurology
External Links
Snippet
Leucine-rich repeat and immunoglobulin domain-containing protein 1 (LINGO-1) is a transmembrane protein that negatively regulates neural regeneration in the central nervous system. LINGO-1 expression is up-regulated after central nerve injury, and is accompanied …
- 208000008513 Spinal Cord Injury 0 title abstract description 105
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Huang et al. | LINGO-1 deficiency promotes nerve regeneration through reduction of cell apoptosis, inflammation, and glial scar after spinal cord injury in mice | |
| Vicuña et al. | The serine protease inhibitor SerpinA3N attenuates neuropathic pain by inhibiting T cell–derived leukocyte elastase | |
| Lang et al. | Adenomatous polyposis coli regulates oligodendroglial development | |
| Slezak et al. | Transgenic mice for conditional gene manipulation in astroglial cells | |
| Koenning et al. | Myelin gene regulatory factor is required for maintenance of myelin and mature oligodendrocyte identity in the adult CNS | |
| US20230263828A1 (en) | Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence | |
| Safari et al. | CRISPR system: a high-throughput toolbox for research and treatment of Parkinson’s disease | |
| US20220143084A1 (en) | Modified natural killer (nk) cells for immunotherapy | |
| Fontana et al. | c-Jun in Schwann cells promotes axonal regeneration and motoneuron survival via paracrine signaling | |
| Strelau et al. | Progressive postnatal motoneuron loss in mice lacking GDF-15 | |
| Wegmann et al. | Persistent repression of tau in the brain using engineered zinc finger protein transcription factors | |
| JP2018518181A (en) | CRISPR / Cas9 complex for introducing functional polypeptides into cells of the blood cell lineage | |
| JP2010509235A (en) | Treatment of multiple sclerosis | |
| Peluffo et al. | Overexpression of the immunoreceptor CD300f has a neuroprotective role in a model of acute brain injury | |
| CA3144687A1 (en) | Cell-type selective immunoprotection of cells | |
| KR20200104282A (en) | Compositions and methods for targeted delivery, expression and regulation of coding ribonucleic acids in tissues | |
| JP2021513866A (en) | Methods and Compositions for Treating Angelman Syndrome | |
| Hamblet et al. | NK cell maturation and cytotoxicity are controlled by the intramembrane aspartyl protease SPPL3 | |
| US20220025461A1 (en) | Methods of detecting, preventing, reversing, and treating neurological diseases | |
| Wu et al. | Targeting a dominant negative rho kinase to neurons promotes axonal outgrowth and partial functional recovery after rat rubrospinal tract lesion | |
| EP3016661B1 (en) | Inhibition of the synthesis of beta-app or of the activity of the a beta peptide in the choroid plexus | |
| CN113577281A (en) | Agents and methods for modulating integrin beta subunit | |
| US20240033332A1 (en) | Agent for activating a neuron | |
| WO2021009763A1 (en) | Methods of treating pain | |
| US20200405884A1 (en) | Crispr-nanoparticles and methods of use in brain disorders |